Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases

Clinical Genitourinary Cancer

Volumn 5, Issue 3, 2006, Pages 232-234

  Rini, Brian I ^a   Shaw, Vanessa ^b   Rosenberg, Jonathan E ^b   Kim, Sindy T ^c   Chen, Isan ^c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

Author keywords

Complete remission; Interferon ; Interleukin 2; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; CELECOXIB; INTERLEUKIN 2; SUNITINIB;

ADRENAL METASTASIS; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CASE REPORT; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LONG TERM CARE; LOW DRUG DOSE; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PANCREATITIS; SIDE EFFECT; TREATMENT RESPONSE;

EID: 33846698219     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2006.n.042     Document Type: Article

References (11)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-2490.
2. Small EJ, Motzer RJ. Interferon for renal cell carcinoma. In: Renal and Adrenal Tumors. Belldegrun A, Ritchie AWS, Figlin RA, et al, eds. New York, NY: Oxford University Press; 2003:381-387.
3. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-3132.
4. Escudier B, Chevreau C, Lasset C, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d'Immunotherape. J Clin Oncol 1999; 17:2039-2043.
5. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24:16-24.
6. Demetri GD, van Oosterom AT, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for GIST. J Clin Oncol 2005; 23(16 suppl):308s (Abstract #4000).
7. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-141.
8. Kim B, Louie AC. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission. Arch Surg 1992; 127:1343-1349.
9. Sherry RM, Pass HI, Rosenberg SA, et al. Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin-2-based immunotherapy. Cancer 1992; 69:1850-1855.
10. Pfannschmidt J, Hoffmann H, Muley T, et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg 2002; 74:1653-1657.
11. Motzer R, Rini B, Michaelson M, et al. Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: updated results from phase II trials. Eur J Cancer Suppl 2005; 3:227 (Abstract #797).